16 September 2024 – Walder Wyss advised CorFlow Therapeutics AG on a series B financing round in the amount of EUR 44 million. The new capital will enable CorFlow to conduct the pivotal MOCA II (MVO with CoFI System Assessment II) study, aiming to validate CorFlow’s CoFl system for the diagnosis of MVO in heart attack patients immediately after stent implantation and enable US market clearance. In addition, it will fund a randomized therapy study to evaluate the treatment effects of therapeutic agents delivered locally through the CoFl system in heart attack patients diagnosed with MVO.

The team was led by Alex Nikitine (Partner, Corporate/M&A) and further included Dominik Aerni (Counsel, Corporate/M&A), Viktoriya Chernaya (Associate, Corporate/M&A), Maurus Winzap (Partner, Tax), Janine Corti (Counsel, Tax) and Viviana Montorfano (Trainee, Corporate/M&A).